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Abstract
Telomerase is thought to play an essential role in tumorigenesis and progression. Its activity is directly correlated
with the expression of its catalytic subunit, human telomerase reverse transcriptase (hTERT). A correlation of tran-
script expression with a poor prognosis has been detected in different human malignancies. However, data on
hTERT in pancreatic ductal adenocarcinoma (PDAC) are purely descriptive so far. Therefore, we evaluated the
impact of hTERT expression on patients’ prognosis. Human telomerase reverse transcriptase mRNA isolates from
56 human microdissected PDAC tissues were analyzed by quantitative reverse transcription–polymerase chain
reaction and multivariate Cox regression hazard test. Elevated hTERT transcript levels were measured in 23 of
56 PDAC tissues, 33 patients showed no detectable transcripts. Unexpectedly, a low expression of hTERT mRNA
levels was associated with a worse prognosis for overall survival (relative risk = 5.33; P = .013) when compared to
high levels, whereas undetectable expression showed an intermediate risk of tumor-related death. These data
challenge previous findings outlining hTERT’s negative impact on overall survival. The risk pattern obtained in
PDAC suggests a more complex regulation of hTERT.
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Introduction
Current molecular oncology strongly suggests that aberrant reactiva-
tion of telomerase is one of the key features of the malignant pheno-
type of a somatic cell [1–4]. Telomerase catalyzes the synthesis and
extension of telomeric DNA, thus leading to inactivation of apopto-
sis and senescence [3,5]. To detect and measure telomerase activity,
the mRNA expression of its catalytic subunit human telomerase re-
verse transcriptase (hTERT) has been proposed as a surrogate marker,
given the fact that mRNA levels correlate directly with telomerase
activity [6,7]. Data on the clinical relevance of hTERT expression
in malignant neoplasias are yet irresolute, although hTERT expres-
sion levels suggest a correlation with a poor prognosis in non–small
cell lung cancer, Wilm tumor, B-chronic lymphocytic leukemia,
acute myelogenous leukemia, colorectal cancer [8–10], and in soft-
tissue sarcoma [11,12].
Pancreatic ductal adenocarcinoma (PDAC) is a dismal disease be-
cause of its aggressive biologic phenotype, characterized by an early
local invasion and high metastatic potential, late clinical presentation,
very poor overall prognosis with a short median survival time of only
a few months after diagnosis (ranging from a few weeks to years), and
high resistance to radiation and chemotherapy [13].
Most recently, telomerase and hTERT activity have been reported
in tumors and pancreatic juice of patients with PDAC [14–18], and
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their possible role in early diagnosis has been proposed. So far, there
are no studies on the impact of hTERT expression on the prognosis
of patients with PDAC. Therefore, we investigated precisely this in a
cohort of 56 PDAC patients from our institution. We microdissected
fresh-frozen tumor tissues to highly enrich neoplastic cells, isolated
mRNA, and applied a quantitative polymerase chain reaction analysis
for hTERTmessage. The impact of the gene expression on prognosis
was determined by a multivariate Cox regression hazard model.
Materials and Methods
Patients
The study comprised a cohort of 56 patients (20 females and
36 males; age range, 34-80 years; mean age, 61.7 years), who were
monitored for a mean observation time of 15.8 months (range,
1-61 months) and whose median survival rate was 14 months (range,
1-49 months). All patients included in the study underwent primary
surgery in the years 2001–2005 at our hospital (Department of
Surgery 1, University of Ulm, Ulm, Germany). Surgical pancreatic
resection specimens were immediately placed on ice and subsequently
snap-frozen and stored at −80°C. All patients gave written informed
consent, and approval of the ethics committee was obtained.
Microdissection
RNAwas isolated using the Innuprep RNA mini-kit (AJ Innuscreen
GmbH, Berlin, Germany). The integrity of the isolated RNA was
confirmed using the Agilent 2100 Bioanalyzer (Agilent Technologies,
Santa Clara, CA). The cryostat tissues were cut into 8- to 10-μm
sections. Microdissection of selected areas containing approximately
50 to 300 neoplastic ductal epithelial cells per area (>4000 cells per
tissue per patient) was carried out by means of laser microdissection
and pressure catapulting (LCM) technique (PALM Microlaser Tech-
nologies, Bernried, Germany) on cresyl violet–stained sections.
Quantitative Reverse Transcription–Polymerase
Chain Reaction
Measurement of hTERT transcript expression levels was per-
formed by quantitative real-time reverse transcription–polymerase
chain reaction as described previously [11,12]. The cutoff levels for
low expression of hTERT were set at 0.00 ag/fg hypoxanthine-
phospho-ribosyl-transferase (HPRT), whereas the cutoff for high ex-
pression was set at the mean value of hTERTexpression (Table W1).
Accordingly, three categories of expression levels were set up: 1, “no
expression” (meaning no detectable mRNA levels); 2, “low expres-
sion” (>0.00 and ≤61 ag hTERTmRNA/fg HPRTmRNA); 3, “high
expression” (>61 ag hTERT/fg HPRTmRNA). Additionally, the “low-
expression” and “high-expression” groups were merged into a joint
group comprising patients with detectable hTERT levels (>0.00 ag
hTERT/fg HPRTmRNA).
Statistical Analysis
Multivariate analysis according to Cox proportional hazards regres-
sion model (with adjustment for tumor staging, type of tumor resec-
tion, and patients’ age) was performed for the analysis of hTERT
mRNA expression. For statistical analyses, SPSS 15.0 software was
used. P < .05 was considered significant.
Results
Of our cohort, 33 had undetectable, 17 had low, and 6 had high
hTERT mRNA levels. The clinical data of the resulting three sub-
groups are listed in Table 1. The data on the impact of the gene
expression on prognosis—as determined by a multivariate Cox re-
gression hazard model—are plotted in Figure 1.
Surprisingly, the analysis of patients of all stages and resection
types showed that patients with low expression levels of hTERTmes-
sage in their PDAC did worse than those with high hTERTmRNA
[relative risk (RR) = 3.39; P = .046; Figure 1]. Unexpectedly again,
patients with undetectable hTERT took an intermediate course
(RR = 1.60; P = .392) when compared with patients presenting high
hTERT levels. Aiming at the analysis of patients treated with a cu-
rative intent, we excluded patients with advanced disease (UICC
stage IVb—concomitance of metastases and/or local R2-resection).
Within this group of patients, the presence of metastases and/or non-
resectable tumor mass might be a more decisive factor of survival
than the expression of hTERT. Interestingly, on such analysis, an
even more explicit, significant association of a worse prognosis in
patients with low expression of hTERT was observed (RR = 5.33;
P = .013) when compared to patients with a high expression profile.
Table 1. Clinical and Histopathologic Data.
Total (n = 56) Low hTERT (n = 17) Not Detectable hTERT (n = 33) High hTERT (n = 6) Patients at Follow-up
Alive* (n = 6) Dead† (n = 50)
Men/Women 36:20 11:6 20:13 5:1 4:2 32:18
Tumor stage
I 2 1 1 0 1 1
II 12 2 8 2 1 11
III 31 7 21 3 4 27
IV 11 7 3 1 0 11
Tumor resection
Radical (R0) 38 9 25 4 5 33
Not radical (R1) 9 2 6 1 1 8
Not radical (R2) 9 6 2 1 0 9
Patients at follow-up
Alive* 6 0 5 1 6
Dead† 50 17 28 5 50
Data are number of patients.
*After an average observation time of 15.8 months (range, 1-61 months).
†Patients died after an average of 14 months (range, 1-49 months), 2 patients died of non–tumor-related reasons.
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Undetectable expression was again associated with a slightly worse
outcome compared with patients with high hTERT levels (RR =
1.83; P = .32). Furthermore, in comparison with the patients showing
undetectable expression of hTERT, the risk of tumor-related death in
those with the low expression profile showed a highly significant in-
crease to 3.8-fold (P = .002). Additionally, we analyzed the impact of
the overall expression of hTERT (merged “low-expression” and “high-
expression” groups; n = 23) on survival. The comparison of this group
with patients presenting undetectable hTERT mRNA levels showed
a tendency—however, not significant—for an overall increased risk
of tumor-related death for patients expressing hTERTmRNA (RR =
1.358; P = .340).
Accordingly, analysis of the three hTERTexpression profile groups
with regard to the 18-month, and the average survival rate was
performed. Of 33 patients with undetectable hTERT expression,
14 were still alive 18 months after diagnosis and surgery or had died
within this time span of non–tumor-related causes. Interestingly, only
1 of 17 patients with low hTERT expression survived this period,
whereas 3 of 6 patients with high hTERT expression were either still
alive or had died due to non–tumor-related causes. The average sur-
vival rate in each group was 9.5 months in the low expression profile
group, 18.2 months for patients with undetectable hTERTexpression,
and 20.8 months for patients with high hTERT expression.
Discussion
The data from this study challenge the present view that telome-
rase activity, strictly and in general, correlates with the biologic be-
havior of a malignant tumor when it comes to complex parameters
such as survival after surgery. The expression of low levels of hTERT
mRNA in PDAC does have a negative impact on patients’ prognosis
and a tendency for an association of hTERT expression in general
with an unfavorable outcome can also be observed in our study.
These data are at first consistent with observations made on other
tumor entities. Among others, hTERToverexpression is (solely) asso-
ciated with a significant poor outcome in soft-tissue sarcoma [11,12],
non–small cell lung cancer [10] and also in combination with cyto-
keratins 19/20 and carcinoembryonic antigen in colorectal cancer
[9]. However, the somewhat better prognosis of patients accompa-
nying a high hTERT expression profile has not been reported for
other malignant tumors up-to-date. This intriguing, more favorable
outcome might indicate a complex and precise regulation of hTERT,
affirming evidence on the complex biology of telomerase regulation.
Current evidence suggests that hTERT expression and its mRNA
levels are mainly controlled at the level of transcription by such means
as hypoxia (through hypoxia response element sites), mitogens, hor-
mones (e.g., estrogen), chromatin remodeling, and cell signaling path-
ways [1,19]. Thus, hTERT’s interrelation with different oncogenes,
including c-Myc, Bcl-2, Her-2, Ras [20–22], p53 [23], and survivin
[11,12,24], and the transcription factors Sp1 and Sp3 [19] has been
suggested to play an important role in cancer progression and telome-
rase control.
However, additional ways of the regulation of hTERT expression
have been proposed and provide possible explanations for the ob-
servations in our study. Thus, regulation of transcript processing,
changes in mRNA half-life [19], specific activation of hTERT pro-
moter by enhancer binding protein-2β [25], or hTERT gene regula-
tion in the form of alternative splicing (e.g., with the active wild type
and inactive b variant, as shown under hypoxic conditions) [26–28]
might account for low hTERT activity despite high mRNA levels
and effectively result in a better prognosis for PDAC patients. Thus,
some alternately spliced deletion variants of hTERT were shown to
be functionally inactive or even impair the function of telomerase
(e.g., the hTERTα− splice variant), causing telomere shortening
and cell death [29,30]. Tumors with a high hTERTexpression profile
might have either less or inactive variants of its mRNA, be subject to
faster degradation or ineffective translation processes, resulting in a
less functional protein expression.
In summary, measurement of hTERT transcription levels identi-
fies groups of PDAC patients with different prognoses, with a patient
group showing a 5.33-fold increased risk of tumor-related death.
This might have an important potential as a predictor of survival.
The oncobiologic role of telomerase activity in PDAC, intriguingly,
remains elusive so far.
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Table W1. Clinical and Histopathologic Data; Quantitative RT-PCR Measurements.
Patient No. Age (years) Survival (months) Censor Stages R-Status HPRT (fg/μl) hTERT (ag/μl) hTERT (ag/fg HPRT)
1 59 13 1 3 0 55.073 4551.100 82.638
2 53 16 1 3 0 955.129 13506.410 14.141
3 60 21 1 2 0 262.407 30491.030 116.197
4 64 39 2 2 1 1069.529 116479.350 108.907
5 40 19 1 3 0 7858.380 406902.390 51.779
6 59 24 1 3 0 231.136 0.000 0.000
7 47 20 1 3 0 386.544 0.000 0.000
8 46 15 1 3 0 173.775 0.000 0.000
9 71 5 1 2 1 373.211 0.000 0.000
10 66 4 1 4 2 27.898 1451.890 52.042
11 70 15 1 3 1 39.054 672.190 17.212
12 67 6 1 3 0 19.760 2330.960 117.963
13 74 3 1 4 2 363.078 10704.520 29.483
14 75 49 1 3 0 578.892 0.000 0.000
15 49 22 1 3 0 189.006 0.000 0.000
16 70 4 1 3 0 45.324 0.000 0.000
17 68 11 1 2 0 265.628 0.000 0.000
18 72 33 1 3 1 206.232 0.000 0.000
19 73 1 4 3 0 28.330 0.000 0.000
20 58 43 1 3 0 1163.919 86123.510 73.994
21 74 61 2 3 0 2410.464 0.000 0.000
22 69 15 1 4 2 149.650 2045.880 13.671
23 43 2 1 4 2 726.099 8015.350 11.039
24 56 5 1 4 2 682.589 0.000 0.000
25 48 9 1 3 0 38.549 0.000 0.000
26 70 8 1 4 2 493.055 14326.020 29.056
27 76 15 1 2 0 274.007 0.000 0.000
28 57 3 1 4 0 1474.944 1223.100 0.829
29 61 14 1 3 0 512.313 3354.430 6.548
30 69 9 1 3 0 262.491 12208.950 46.512
31 47 2 1 3 0 90.737 1961.580 21.618
32 52 29 1 2 0 467.628 0.000 0.000
33 38 4 1 4 2 138.001 0.000 0.000
34 65 16 1 2 0 105.754 6372.660 60.259
35 75 13 1 2 0 914.723 8537.610 9.334
36 60 4 1 4 1 943.189 0.000 0.000
37 61 37 1 3 0 466.807 0.000 0.000
38 62 16 1 2 1 136.162 0.000 0.000
39 80 33 1 3 0 92.629 0.000 0.000
40 69 1 4 3 0 343.182 0.000 0.000
41 42 3 1 4 2 259.850 114535.130 440.775
42 52 28 2 3 0 5.231 0.000 0.000
43 52 13 1 3 0 38.957 0.000 0.000
44 71 23 1 2 0 71.127 0.000 0.000
45 64 23 2 3 0 121.342 0.000 0.000
46 69 19 2 3 0 458.081 0.000 0.000
47 68 19 2 1 0 1453.104 0.000 0.000
48 34 6 1 3 1 943.603 54612.080 57.876
49 61 12 1 1 0 209.867 7199.790 34.306
50 71 12 1 2 0 28.472 0.000 0.000
51 66 17 1 3 0 129.289 0.000 0.000
52 74 17 1 2 0 584.660 0.000 0.000
53 67 17 1 3 0 29.757 0.000 0.000
54 67 6 1 3 1 192.573 0.000 0.000
55 69 5 1 4 2 465.172 6802.180 14.623
56 55 8 1 3 1 2734.667 0.000 0.000
Survival: postoperatively until follow-up or death.
Censor: 1 indicates died due to tumor; 2, alive at follow-up (without recurrence or metastasis); 4, died due to non–tumor-related causes.
Stages: 1 indicates stage I; 2, stage II; 3, stage III; 4, stage IV.
R-Status—resection type: 0 indicates R0; 1, R1; 2, R2.
